Latest news with #RESOLVE
Business Insider
07-05-2025
- Business
- Business Insider
Eupraxia Pharmaceuticals reports Q1 net loss $6.8M vs. $6.2M last year
The Company had cash of $27.5M as of March 31, down from $33.1M at the end of the Q4.'We recently achieved a significant clinical milestone with the release of positive nine-month data from our ongoing open-label, dose-escalation Phase 1b/2a RESOLVE trial, which continue to support EP-104GI as a potentially transformative therapy for eosinophilic esophagitis,' said James Helliwell, CEO of Eupraxia. 'The sustained or improved treatment outcomes observed over a nine-month period after a single treatment with 48mg dose of EP-104GI is a promising finding in the treatment of EoE with an injectable delivery system. We believe these results provide further evidence of the precision and durability of our DiffuSphere technology and provide a strong foundation as we advance into higher-dose cohorts in the coming quarters.' Protect Your Portfolio Against Market Uncertainty
Yahoo
16-04-2025
- Health
- Yahoo
Progyny to Host Events Honoring Individuals, Families and Infertility Throughout National Infertility Awareness Week® and Canadian Fertility Awareness Week®
As awareness around the need for expanded access and coverage of fertility grows, Progyny lifts off the conversation and provides a platform for the millions of individuals facing family building challenges NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced a series of events to commemorate National Infertility Awareness Week (NIAW) and Canadian Fertility Awareness Week (CFAW), both recognized from April 20-26, 2025. At the heart of the events is the company's mission to educate and empower more women and families in achieving their family building goals, with longtime Progyny partner and industry leader RESOLVE: The National Infertility Association lending its voice to the programming for NIAW, and Fertility Matters Canada for CFAW. 'Every year Progyny is helping more and more people achieve their goals of family building with access to high-quality, equitable fertility care—we will continue to work until everyone in need is able to realize their dreams of parenthood," said Pete Anevski, CEO, Progyny. 'NIAW and CFAW are powerful reminders of how many people are navigating this journey, and the opportunity we have as an industry, and as a community, to create change and make a lasting impactful difference.' At the heart of this year's campaign are the powerful voices of public figures and advocates who are courageously sharing their personal fertility journeys to raise awareness and reduce stigma associated with this medical condition. Celebrities and influencers – including Jessi and Alessio Pasini and Demi and Tom Schweers – are sharing their stories to amplify the importance of accessible fertility care. 'Through our journey, we've seen firsthand how important accessibility to fertility care, and awareness are. We're incredibly honored to stand alongside Progyny and RESOLVE to illuminate conversations about fertility struggles and bring these experiences out of the shadows,' said Jessi and Alessio Pasini. Their voices will be featured throughout a week of events across North America, designed to spark conversation, build community, and shine a light on the realities of infertility. These awareness events include: April 21st | Ringing the Nasdaq Stock Market Opening Bell (New York) – Progyny, RESOLVE, leading employers, and industry advocates will ring the Opening Bell to highlight the importance of comprehensive fertility benefits from 9:15AM – 9:30AM ET. April 21st | Lighting of the Empire State Building (New York) – Progyny and RESOLVE, joined by infertility advocates Jessi and Alessio Pasini (The Pasinis), will light the Empire State Building orange—the official color of infertility awareness—for the fourth consecutive year. April 22nd | 'Infertility Unfiltered' Panel Event (New York) – Progyny will host a panel discussion on education, support, and access to fertility care, featuring fertility advocates Demi and Tom Schweers, Progyny's Chief Medical Officer Dr. Janet Choi, and fertility patient and Progyny member Erin Antoniak. The panel, moderated by HR Brew's Courtney Vinopal, will also showcase an art collection by The ART of Infertility, featuring work from artists who have gone through fertility challenges, depicting the emotional and physical journey. April 22nd | "Light the Night" Event (Chicago) – Progyny will join forces with leading Midwest employers and nonprofit advocates for an evening of connection and awareness. April 24th | Lighting of the CN Tower (Toronto) – In partnership with Fertility Matters Canada, Progyny will join partners and supporters to recognize Canadian Fertility Awareness Week. Advocates will gather in Toronto to show support for the fertility community, coinciding with the lighting of the CN Tower and other landmarks across Canada in green—the country's official fertility awareness color—for the third year in a row. 'National Infertility Awareness Week is about breaking the silence, building community, and driving change for the one in six people struggling to conceive. We are deeply grateful for Progyny's continued support in amplifying voices and ensuring no one walks this challenging path alone,' said Barbara Collura, President and CEO, RESOLVE. 'Access to care, education, and benefits are critical, and Progyny's continued leadership in this space makes a meaningful difference for so many.' The Opening Bell ceremony will be webcasted online. If you'd like to view the ceremony live, visit from 9:15AM – 9:30AM ET. If you would like to learn more about the Empire State Building, visit To learn more about Progyny, visit To learn more about RESOLVE, visit To learn more about Fertility Matters Canada, visit About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit About RESOLVE The National Infertility Association Established in 1974, RESOLVE: The National Infertility Association is a non-profit organization with the only established nationwide network mandated to promote reproductive health and to ensure equal access to all family building options for anyone experiencing infertility or challenges in building their family. RESOLVE addresses this public health issue by providing community to all who need it, connecting them with others who can help, empowering them to find resolution and giving voice to their demands for access to all family building options. For more information, visit About Fertility Matters Canada Fertility Matters Canada (FMC) is the leading national patient-focused organization providing free support, public education, and advocacy for equitable access to fertility care in Canada. Whether you are considering your future fertility, are currently on a fertility journey, are facing childlessness after infertility, have experienced a miscarriage or loss, or are seeking support or information, FMC is here to help you. We grew out of a volunteer group in Ottawa called the Infertility Self Support Group (ISSG), which began in 1983. Today, FMC is a national charitable organization supporting more than 1 in 6 Canadians who are struggling with their fertility or who need access to fertility care to build their family. In 2007, FMC launched Canadian Infertility Awareness Week (CIAW) to raise awareness and hope in the fertility community. In 2023, CIAW became Canadian Fertility Awareness Week (CFAW), a more inclusive campaign raising awareness of the struggles and stories of all those needing access to fertility care. For Further Information, Please Contact: Media:Alexis Fordmedia@ Investors:James Hartinvestors@ in to access your portfolio
Yahoo
02-04-2025
- Health
- Yahoo
Trump Guts IVF Research After Saying He's 'Fertilization President'
Despite dubbing himself the 'Father of IVF,' Donald Trump actually won't be funding federal infertility research. The administration fired a team of researchers focused on infertility research and assisted reproductive technology Tuesday afternoon, the latest group to lose their jobs in sweeping new cuts at the Centers for Disease Control and Prevention. 'It is vital that the CDC, our nation's public health agency, employs doctors and scientists who understand infertility, a disease that impacts one in six people worldwide,' Barbara Collura, President and CEO of the national infertility group RESOLVE, said in a statement. 'Following today's layoffs at the CDC, there will be no experts on infertility who will be able to inform public policy, brief members of Congress, publish articles and reports, and advance public awareness on the causes and treatments for infertility.' The team was responsible for tracking IVF cycles & creating and maintaining infertility-related databases. Speaking with HuffPost's Alanna Vagianos, Collura said that questions remain regarding the future of that data—if it will be updated, and who would be doing the updating. 'That's a lot of information and knowledge that walked out the door today,' Collura said. The cut comes barely a week after Trump referred to himself as the 'fertilization president' during a Women's History Month event. Trump bragged about his purported efforts to expand IVF access and promised that there would be 'tremendous goodies in the bag for women,' including 'the fertilization and all the other things we're talking about.' So far, the Trump administration—directed by Elon Musk's Department of Government Efficiency—has fired more than 100,000 federal employees. But tens of thousands more government jobs are expected to be on the chopping block as Trump pursues a second round of 'voluntary' buyouts. More than 10,000 jobs are expected to be cut at the Department of Health and Human Services, which encompasses the CDC. HHS Secretary Robert F. Kennedy Jr. has proposed downsizing the agency's 82,000-person workforce by nearly a quarter. Other shuttered departments were responsible for research and policy recommendations on older adults, disabilities, HIV, minority health, mine safety, and smoking.
Yahoo
01-04-2025
- Health
- Yahoo
Kindbody to Host Nationwide Virtual Event to Advocate for Infertility Awareness and Improved Access to Fertility Care During National Infertility Awareness Week®
Leading National Fertility Clinic Network to Offer 20% Off Fertility Services Throughout the Month of April NEW YORK, April 1, 2025 /PRNewswire/ -- Kindbody, the leading national fertility clinic network and global family-building benefits provider for employers, today announced it will host a nationwide virtual event to advocate for infertility awareness and improved access to fertility care during National Infertility Awareness Week (NIAW) April 20 - 26, 2025. Dr. Roohi Jeelani, Chief Medical Officer, Growth and Reproductive Endocrinologist at Kindbody, will be joined by Alise Powell, Director of Government Affairs at RESOLVE: The National Infertility Association, to discuss the challenges people with infertility face, how to engage in policy efforts to improve access to fertility care, and how to advocate for workplace fertility benefits. Additionally, the company will extend a 20% discount on fertility treatments and services, including egg freezing, intrauterine insemination (IUI), in vitro fertilization (IVF), and embryo banking, throughout the entire month of April. Infertility is widespread, more common than diseases like cancer or diabetes. One in six people are affected by infertility worldwide, according to the World Health Organization. Dr. Roohi Jeelani said, "In today's evolving healthcare landscape, advocating for fertility treatments has never been more crucial. With increasing restrictions on reproductive healthcare and the high cost of care, many individuals and couples face overwhelming barriers to starting or growing their families." She added, "Through this virtual event and fertility treatment discount we aim to raise awareness, inspire advocacy, and ensure fertility treatments are within reach for more people." The Kindbody event Become an Infertility Advocate with RESOLVE will take place virtually Thursday, April 24 at 1:30pm ET. Registration is now open at New and existing patients can redeem the 20% discount at any one of Kindbody's 27 U.S. clinics by using code: 20NIAW25 when booking a consultation on the company's website or by calling 1-855-KND-BODY. Current Kindbody patients can submit the code through the company's proprietary patient portal. In order to qualify for the promotion, patients must schedule their treatment by April 30, 2025 and begin treatment by August 30, 2025. National Infertility Awareness Week is a movement, founded in 1989 by RESOLVE: The National Infertility Association. RESOLVE's work is more vital now than ever because the landscape of reproductive healthcare is becoming increasingly complex and challenging. Alise Powell said, "We frequently hear from our patient community that advocacy is a powerful way to regain control during what can often be a challenging family building journey. For decades, RESOLVE has been at the forefront of empowering patients to engage with lawmakers on issues that matter most to them." Kindbody owns and operates 27 signature clinics throughout the U.S. in Arkansas, California, Colorado, District of Columbia, Georgia, Illinois, Maryland, Michigan, Missouri, New Jersey, New York, Ohio, Texas, Washington, and Wisconsin. To schedule an appointment, visit About Kindbody Kindbody is the leading U.S. fertility clinic network and global family-building benefits provider for employers on a mission to make fertility care more affordable and accessible for all. Kindbody serves patients at 27 state-of-the-art signature clinics and IVF labs, 400+ partner clinics, and in 113 countries around the world. Trusted by more than 133 employers, Kindbody's physician-led model covers the full-spectrum of reproductive healthcare including fertility assessments, fertility preservation, genetic testing, IVF, donor and surrogacy services, adoption, postpartum care, and menopause support. Kindbody is the only fertility benefits provider that serves patients directly, delivering a seamless, integrated experience with superior health outcomes at lower cost. Recognized for technology innovation and industry leadership, Kindbody has been named to CNBC Disruptor 50, Fast Company's Brands that Matter, Forbes Best Startup Employers, Inc.'s Best In Business list of most admired companies, as well as Deloitte Technology Fast 500™, which recognizes the fastest growing and most innovative technology companies in North America. Founded in 2018, Kindbody has raised more than $315 million in debt and equity funding from leading investors including Perceptive Advisors, JP Morgan Chase's Morgan Health, GV, RRE Ventures, Claritas Health Ventures, Rock Springs Capital, Distributed Ventures, Whatif Ventures and TQ Ventures. Visit and follow us on Instagram and Linkedin. Contact: Margaret Ryan Kindbody press@ View original content to download multimedia: SOURCE Kindbody Sign in to access your portfolio
Globe and Mail
20-03-2025
- Business
- Globe and Mail
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
VICTORIA, BC , /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b /2a RESOLVE trial for EP-104GI as a potential treatment for eosinophilic esophagitis," said Dr. James Helliwell , Chief Executive Officer of Eupraxia. "The results from the first six cohorts of the trial show that precise, localized delivery of EP-104GI at higher doses is leading to further improvements in tissue health and symptom reduction outcomes. In addition, during the fourth quarter, we raised C$44.5 million , significantly strengthening our balance sheet and ensuring the Company is well-funded into the second half of 2026." Recent Operational and Financial Highlights On October 2, 2024 , the Company announced the appointment of Dr. Amanda Malone as the Chief Operating and Scientific Officer of the Company. On October 10, 2024 , the Company announced a poster presentation at the United European Gastroenterology Week 2024 featuring data from cohorts one through four of Eupraxia's ongoing RESOLVE trial in EoE. On October 15, 2024 , the Company announced that Phase 2b data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis was published in leading peer reviewed medical journal The Lancet Rheumatology. On October 28, 2024 , the Company announced two poster presentations at the American College of Gastroenterology 2024 Annual Scientific Meeting centered on EP-104GI for the treatment of EoE. One poster received a Presidential Award from the conference, which is a distinction for high quality, novel, unique, and interesting research, while the other was designated an "Abstract of Interest". On October 31, 2024 , the Company announced the closing of a non-brokered private placement for gross proceeds of C$44.5 million , the appointment of Mr. Joseph Freedman to its Board of Directors, and the termination of its C$12 million convertible debt facility. On November 12, 2024 , the Company announced positive 12-week data from the fifth cohort of the ongoing RESOLVE trial in patients with eosinophilic esophagitis ("EoE"), noting increasingly positive data on efficacy and safety outcomes as well as emerging evidence of improved patient responses related to higher dosing levels. On November 14, 2024 , the Company announced a poster presentation at the American College of Rheumatology Convergence 2024 Annual Meeting covering data from Eupraxia's Phase 2b SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis. Subsequent to quarter end, on February 18, 2025 , the Company announced the return of seasoned capital markets executive Alex Rothwell to the role of Chief Financial Officer, succeeding the retiring Bruce Cousins . Subsequent to quarter end, on February 25, 2025 , the Company announced positive 12-week data from the sixth cohort of the ongoing RESOLVE trial in patients with EoE noting no adverse events and continued positive data on efficacy and safety outcomes as well as further evidence of improved patient responses tied to higher dosing levels. Fourth Quarter 2024 Financial Review The Company incurred a net loss of $7.5 million for the three months ended December 31, 2024 , versus a net loss of $10.6 million for the three months ended December 31, 2023 . The decrease in net loss was primarily due to lower research and development costs and reduced other expenses incurred during the period. The Company had cash of $33.1 million as of December 31, 2024 , up from $19 .3 million at the end of the fourth quarter of 2023. These funds are being used to fund clinical trials in EP-104 and the remainder of the proceeds will be used for general and administrative expenses, working capital needs and other general corporate purposes. The Company anticipates that existing cash reserves, and anticipated proceeds from in-the-money warrants, will be sufficient to fund the Company to the third quarter of 2026. As of December 31, 2024 , the Company had 35,641,603 common shares issued and 8,905,638 preferred shares outstanding. Potential Impact of Tariffs Management continues to monitor the North American trade situation stemming from the February 2025 announcement by the U.S. government of proposed 25% tariffs on selected imported Canadian goods, and the subsequent Canadian announcement of planned retaliatory tariffs on selected imported U.S. goods. Eupraxia sources its active pharmaceutical ingredient ("API") (fluticasone propionate) from the United States and clinical supplies of EP-104 IAR and EP-104GI are manufactured in the U.S. by a third-party. The Company expects to continue to access both API and manufactured products from the U.S. The Company maintains U.S. dollar balances to pay U.S. dollar expenses and to minimize the impact of short-term fluctuations in exchange rates. Management continues to assess the potential direct and indirect impacts of tariffs, counter-tariffs and other trade protection measures on Eupraxia's business and will take those steps it deems necessary to attempt to mitigate any impact as the situation evolves. Financial Statements and Management Discussion & Analysis Please see the audited consolidated financial statements and related MD&A for more details. The audited consolidated financial statements for the year ended December 31, 2024 , and related MD&A, have been reviewed and approved by Eupraxia's Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed under the Company's profile on EDGAR at and on SEDAR+ at and is also available on the Company's website at About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas. Eupraxia's EP-104GI is currently in a Phase 1b /2a trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: Notice Regarding Forward-looking Statements and Information This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's products; potential pipeline indications; expectations regarding the funding of the Company's operations to the third quarter of 2026, and the use of cash reserves and proceeds from the exercise of warrants; and expectations regarding continued access to both API and manufactured products from the U.S., as well as ongoing monitoring and necessary actions to attempt to mitigate any impact of tariffs, counter-tariffs and other trade protection measures on the Company's business. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the potential impact of tariffs on the cost of the Company's API and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ ( and EDGAR ( Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
